Forward Regulatory Plan 2019-2021: Regulations Amending the Narcotic Control Regulations under the Controlled Drugs and Substances Act to make all products containing codeine available by prescription only while ensuring access to these medications

Title of Regulatory Initiative

Regulations Amending the Narcotic Control Regulations under the Controlled Drugs and Substances Act to make all products containing codeine available by prescription only while ensuring access to these medications

Enabling Act

Controlled Drugs and Substances Act

Description

Health Canada is proposing to amend the Narcotic Control Regulations under the Controlled Drugs and Substances Act to balance concerns that low-dose codeine can lead to dependence and problematic use, while ensuring that Canadians would be able to access it.

Regulatory cooperation efforts (domestic and international)

Not Applicable

Potential impacts on Canadians, including businesses

The proposed regulatory amendment applies to the health care sector and would balance concerns that low-dose codeine can lead to dependence and problematic use, while ensuring that Canadians would be able to access it.

Stakeholders that may be impacted by the change include: pharmacies, industry, Canadians, and health professionals.

Consultations

Canadians had the opportunity to provide comments on the proposed changes that would require all products containing codeine to be sold by prescription only, during the Notice to Interested Parties Canada Gazette public comment period, which started on September 9, 2017 and lasted 60 days.

Canadians will have the opportunity to provide comments on the regulatory proposal during the Canada Gazette, Part I public comment period, which is expected to take place in spring 2019 and last 70 days.

Information on previous consultations and details on upcoming opportunities for consultation in the area of controlled substances can be found on the Canada.ca website.

Further information

Additional information can be requested from the Departmental contact.

Departmental contact information

Jennifer Geduld
Manager
Controlled Substances Directorate
Controlled Substances and Cannabis Branch
Health Canada

Telephone: 613-218-9821
Email address: hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca

Date the regulatory initiative was first included in the Forward Regulatory Plan

October 1, 2018

Consult Health Canada's acts and regulations web page for:

  • a list of acts and regulations administered by Health Canada
  • further information on Health Canada's implementation of government-wide regulatory management initiatives

Consult the following for links to the Cabinet Directive on Regulation and supporting policies and guidance, and for information on government-wide regulatory initiatives implemented by departments and agencies across the Government of Canada:

To learn about upcoming or ongoing consultations on proposed federal regulations, visit:

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: